New #JITC article: Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types bit.ly/40P4spH Ryon Graf, PhD Foundation Medicine

🆕review article in press: Efficacy assessment in phase I clinical trials: endpoints and challenges Mohamed A Gouda, Ignacio Garrido-Laguna, Pablo A. Ballesteros

Very nice review on HER3 targeting by Helena Yu and colleagues. A bispecific HER3xHER2 mAb was recently approved in thoracic oncology. However, despite many strategies studied to date, only anti-HER3 ADCs have shown benefit in breast oncology to date. nature.com/articles/s4157…

Concordance of ctDNA & tissue genomic profiling in advanced BTC Journal of Hepatology doi.org/10.1016/j.jhep… 🔎RWD 👉85% concordance btw tissue and ctDNA 👉targetable alterations in 34.3% by ctDNA 👉high ctDNA VAF associated w/ poor outcomes 🧐ctDNA aids in guiding personalized 💊

A Society for Immunotherapy of Cancer vision statement on accelerating #clinicaltrials to get 100 immunotherapy regulatory approvals in 10 years. Excited to be part of this effort for the paper, for our field but most importantly for the people w #cancer we are working to #cure! jitc.bmj.com/content/13/3/e…

🛰️SPACE-FLOT full article published BJS ❓Neoadjuvant FLOT, surgery, then adjuvant FLOT all comers? pathological response guided? ➡️International retrospective, 1887 pts ✅Adjuvant FLOT benefits in partial responders (PR) ❌But not in minimal responders (MR) or

Evolution of HER2 testing over 40 yrs. IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging. We presented data with HS-HER2 to predict T-DXd activity at #ESMO24. More data coming at #ASCO25. Stay tuned. nature.com/articles/s4157…

🔬Designing clinical trials for rare cancers ASCO ✅Innovative designs ✅Precision med and NGS ✅Tumor-agnıstic therapies ✅Colloboration ✅AI 👉doi.org/10.1200/EDBK-2… Vivek Subbiah, MD Razelle Kurzrock, MD OncoAlert Cholangiocarcinoma Foundation #cancer #oncology #MedX

Accelerated preview of Mutograph paper on colorectal cancer published in nature today. Results suggest that increase in early onset colorectal cancer may be linked to childhood exposure to some types of E.Coli bacteria that produce genotoxin colibactin. nature.com/articles/s4158…

Our Cancer Discovery review article on “40 years of ADCs” will be open access during #AACR25. Great for getting up to speed and prepare for the many ADC advancements expected this year. Read it here: doi.org/10.1158/2159-8…

We call for a paradigm shift in development of immunotherapy drugs, especially bispecifics. Leukemia Journal These drugs have therapeutic effects that last a long time. We need to reduce frequency and switch to limited duration treatment to avoid toxicity. nature.com/articles/s4137…

NCCN 2025 Gastric Cancer Guidelines are out! HER2, PD-L1, CLDN18.2, MSI/MMR testing standard for advanced disease. Immunotherapy combinations for HER2+, PD-L1+, MSI-H, and CLDN18.2+ tumors are emphasized. The new algorithm includes CRC and HIPEC in selected patients. OncoAlert

Microbes in the gut and other body locations can influence cancer development, progression, and response to treatment. This Review summarizes current evidence regarding the human microbiome and cancer. ja.ma/3Svwdjl

The tyranny of PBD ADCs: ADCT-602 has been discontinued! My take for #AACR25 educational session👇 Read more about ADC payload potency and MTD in our recent Cancer Discovery review: aacrjournals.org/cancerdiscover… or in our Cancer Cell commentary: cell.com/cancer-cell/fu… (both free access!)

Time to rethink cancer trials. 🧬 Precision oncology demands: -Early molecular profiling -Flexible evidence (Phase 1/2, real-world) -Tumor-agnostic approvals - Global equity New era, new rules. Nature Cancer OncoAlert Vivek Subbiah, MD G Curigliano MD PhD Razelle Kurzrock, MD ASCO ESMO - Eur. Oncology ECOG-ACRIN Cancer Research Group

Increased risk of 13 different cancers with an elevated BMI NEJM #obesity

HER2 testing: evolution and update for a companion diagnostic assay NatureRevClinOncol doi.org/10.1038/s41571… 👉Accurate & precise identification of HER2 status is increasingly important 👉New approaches evolving.. quantitative immunofluorescence & RNA-based assays 👏great

Ultimate review - Bispecific antibodies in NSCLC #LCSM doi.org/10.1200/EDBK-2…

Recently published: Racial Disparities in Analgesic and Psychiatric Medication Use during End-of-Life Care in Advanced-Stage #ColorectalCancer: A Retrospective Cohort Study, by John M. Allen et al. doi.org/10.1158/2767-9… 𝗝𝗼𝗵𝗻 𝗔𝗹𝗹𝗲𝗻 David DeRemer #HealthEquity #OpenAccess

Use of bronchial wash fluid for NGS testing in NSCLC reported JCO Precision Oncology. Concordance between bronchial wash and tissue was 94%. ctDNA from bronchial wash was more comparable to tissue than plasma in this study. ascopubs.org/doi/10.1200/PO…